Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
收藏NBER2014-07-01 更新2025-01-04 收录
下载链接：
https://www.nber.org/papers/w20292
下载链接
链接失效反馈官方服务：
资源简介：
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market
提供机构：
美国国家经济研究局
创建时间：
2014-07-01
